BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kou D, Dwaraknath S, Fischer Y, Nguyen D, Kim M, Yiu H, Patel P, Ng T, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria. Mol Pharmaceutics 2017;14:3577-87. [DOI: 10.1021/acs.molpharmaceut.7b00593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Kou D, Zhang C, Yiu H, Ng T, Lubach JW, Janson M, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound. Mol Pharm 2018;15:1607-17. [PMID: 29522347 DOI: 10.1021/acs.molpharmaceut.7b01143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Jamei M, Abrahamsson B, Brown J, Bevernage J, Bolger MB, Heimbach T, Karlsson E, Kotzagiorgis E, Lindahl A, Mcallister M, Mullin JM, Pepin X, Tistaert C, Turner DB, Kesisoglou F. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary. European Journal of Pharmaceutics and Biopharmaceutics 2020;155:55-68. [DOI: 10.1016/j.ejpb.2020.08.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
3 Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnürch A, Butler J, Ceulemans J, Davies N, Dupont D, Flaten GE, Fotaki N, Griffin BT, Jannin V, Keemink J, Kesisoglou F, Koziolek M, Kuentz M, Mackie A, Meléndez-Martínez AJ, McAllister M, Müllertz A, O'Driscoll CM, Parrott N, Paszkowska J, Pavek P, Porter CJH, Reppas C, Stillhart C, Sugano K, Toader E, Valentová K, Vertzoni M, De Wildt SN, Wilson CG, Augustijns P. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev 2021;171:289-331. [PMID: 33610694 DOI: 10.1016/j.addr.2021.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
4 Kambayashi A, Dressman JB. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro–In Silico–In Vivo Approach: Case Examples—Dipyridamole, Prasugrel, and Nelfinavir. Journal of Pharmaceutical Sciences 2019;108:584-91. [DOI: 10.1016/j.xphs.2018.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Li J, Tsinman K, Tsinman O, Wigman L. Using pH Gradient Dissolution with In-Situ Flux Measurement to Evaluate Bioavailability and DDI for Formulated Poorly Soluble Drug Products. AAPS PharmSciTech 2018;19:2898-907. [PMID: 30209787 DOI: 10.1208/s12249-018-1164-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]